Movement Alert｜Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound

Market Focus06-24 09:49

On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.

On the news front, CITIC Construction Investment and Industrial Securities recently published research reports issuing Buy and Overweight ratings respectively, while the broader biotech sector staged a collective rebound. CITIC Construction Investment noted that Akeso has established itself as a domestic leader in bispecific antibodies with its globally leading Tetrabody platform, forming a dual strategic direction of IO 2.0 and ADC. Industrial Securities maintained its Overweight rating, stating that the ivonescimab HARMONi-6 OS data represents a milestone achievement with projected revenue potential exceeding USD 15 billion by 2033.

Additionally, the company previously approved a buyback plan of up to HKD 200 million combined with management planned purchases of up to HKD 50 million, sending clear capital support signals. Peer stocks also rallied, with Kelun-Biotech up 6.88%, Remegen up 4.26%, and BeiGene up 3.36%, reflecting broad sector recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102387263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102387263","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound","media":"Market Focus","content":"<p><p>On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.</p><p>On the news front, CITIC Construction Investment and Industrial Securities recently published research reports issuing Buy and Overweight ratings respectively, while the broader biotech sector staged a collective rebound. CITIC Construction Investment noted that Akeso has established itself as a domestic leader in bispecific antibodies with its globally leading Tetrabody platform, forming a dual strategic direction of IO 2.0 and ADC. Industrial Securities maintained its Overweight rating, stating that the ivonescimab HARMONi-6 OS data represents a milestone achievement with projected revenue potential exceeding USD 15 billion by 2033.</p><p>Additionally, the company previously approved a buyback plan of up to HKD 200 million combined with management planned purchases of up to HKD 50 million, sending clear capital support signals. Peer stocks also rallied, with Kelun-Biotech up 6.88%, Remegen up 4.26%, and BeiGene up 3.36%, reflecting broad sector recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.</p><p>On the news front, CITIC Construction Investment and Industrial Securities recently published research reports issuing Buy and Overweight ratings respectively, while the broader biotech sector staged a collective rebound. CITIC Construction Investment noted that Akeso has established itself as a domestic leader in bispecific antibodies with its globally leading Tetrabody platform, forming a dual strategic direction of IO 2.0 and ADC. Industrial Securities maintained its Overweight rating, stating that the ivonescimab HARMONi-6 OS data represents a milestone achievement with projected revenue potential exceeding USD 15 billion by 2033.</p><p>Additionally, the company previously approved a buyback plan of up to HKD 200 million combined with management planned purchases of up to HKD 50 million, sending clear capital support signals. Peer stocks also rallied, with Kelun-Biotech up 6.88%, Remegen up 4.26%, and BeiGene up 3.36%, reflecting broad sector recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1102387263","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102387263","pubTimestamp":1782265763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.On the news front, CITIC Construction Investment and Industrial Securities...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨3.1%生物科技板块反弹多家券商给予买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.On the news front, CITIC Construction Investment and Industrial Securities recently published research reports issuing Buy and Overweight ratings respectively, while the broader biotech sector staged a collective rebound. CITIC Construction Investment noted that Akeso has established itself as a domestic leader in bispecific antibodies with its globally leading Tetrabody platform, forming a dual strategic direction of IO 2.0 and ADC. Industrial Securities maintained its Overweight rating, stating that the ivonescimab HARMONi-6 OS data represents a milestone achievement with projected revenue potential exceeding USD 15 billion by 2033.Additionally, the company previously approved a buyback plan of up to HKD 200 million combined with management planned purchases of up to HKD 50 million, sending clear capital support signals. Peer stocks also rallied, with Kelun-Biotech up 6.88%, Remegen up 4.26%, and BeiGene up 3.36%, reflecting broad sector recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102387263","isCrawlerRequest":true}